

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: LYVENOB (Cycle 1)

(Page 1 of 2)		
DOCTOR'S ORDERS Wt_	kg	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form		
DATE: To be given:	Cycle # 1	
 Low-medium TLS Risk- Days 1, 8, 15 chemo must be given on a Thursday High TLS Risk – chemo not restricted to a Thursday and consider inpatient admission 		
Delay treatment week(s)		
CBC & Diff day of treatment		
Day 1: May proceed with doses as written if within 72 hours ANC greater than or equal to 1.0 x 10 ⁹ /L, platelets greater than or equal to 25 x 10 ⁹ /L, total bilirubin less than or equal to 3 x ULN		
Day 2: May proceed with doses as written if within 24 hours ANC greater than or equal to 1.0 x 10 ⁹ /L, platelets greater than or equal to 25 x 10 ⁹ /L, chemistry normal		
Dose modification for: Hematology Other Toxicity		
Proceed with treatment based on blood work from		
Tumor Lysis Prophylaxis: Patient to take own supply. RN/Pharmacist to confirm		
allopurinol 300 mg PO daily start at least 72 hours prior to first dose of oBINutuzumab		
Advise patient to drink 1.5 to 2 L of fluids daily starting 48 hours prior to first dose of oBINutuz Cycle 3 Day 1	umab and continue until	
PREMEDICATIONS for oBINutuzumab INFUSION:		
Patient to take supply of oral medications. RN/Pharmacist to confirm		
If ordered, ensure patient has taken steroid the day(s) prior to infusion.		
Days 1 and 2:		
60 minutes prior to infusion: dexamethasone 20 mg IV 30 minutes prior to infusion: acetaminophen 650 to 975 mg PO and diphenhydrAMINE 9	50 mg PO	
Days 8 and 15:		
If reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than Day 2 oBINutuzumab, then 60 minutes prior to treatment: dexamethasone 20 mg IV		
30 minutes prior to treatment: acetaminophen 650 mg to 975 mg PO and diphenhydrAMINE 50 mg PO		
Have Hypersensitivity Reaction Tray and Protocol Available		
TREATMENT:		
Day 1: oBINutuzumab 100 mg IV in 100 mL NS on Day 1.		
Administer over 4 hours at 25 mg/h . Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
Day 2:		
oBINutuzumab 900 mg IV in 250 mL NS on Day 2.		
Start at 50 mg/h ; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic. Refer to protocol for resuming infusion following a reaction.		
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discore existing symptoms occur, stop infusion and page physician.	mfort or exacerbation of any	
Days 8 and 15:		
oBINutuzumab 1000 mg IV in 250 mL NS on Days 8 and 15.		
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate was 100 mg/h or faster: Start at 100 mg/h . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
DOCTOR'S SIGNATURE:	SIGNATURE:	
DOULOR & SIGNALORE.		
	UC:	
BC Cancer Provincial Preprinted Order LYVENOB (Cycle 1) Created: 1 Feb 2022 Revised: 1 Mar 2025 (Premedications and rate clarified, observation, vitals,	and tests updated)	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca</u> and according to acceptable standards of care

PROTOCOL CODE: LYVENOB (Cycle 1)

(Page 2 of 2)

Date:	
RETURN APPOINTMENT ORDERS	
Return in three weeks or <u>weeks</u> for Doctor and Cycle 2.	
Note: Treatment dates for Cycle 1 Days 1, 8 and 15, and Cycle 2 Day 8 must be on a Thursday for Low-Medium TLS risk patients- refer to page 1 for TLS risk category	
For Cycle 1, book treatment on Day 1, Day 2, Day 8 and Day 15	
For Cycle 2, book treatment on Day 8 (i.e. 4 weeks from Cycle 1 Day 1)	
Prior to Cycle 1 Day 2: CBC & Diff, potassium, calcium, phosphate, uric acid, creatinine, LDH, albumin	
Prior to Cycle 2: CBC & Diff, potassium, calcium, phosphate, uric acid, creatinine, total bilirubin, ALT, LDH, albumin	
If clinically indicated:	
HBV viral load	
Other tests:	
Consults:	
See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: